July 2007: Volume 33, Number 7
IVD Market Forecast: Healthy Growth Ahead
U.S. demand for in vitro diagnostic (IVD) products will grow 5.1% annually until 2011, when it will total $19.5 billion, a recently released report forecasts. In Vitro Diagnostics, issued by the market research firm The Freedonia Group (Cleveland, Ohio) predicts that clinical chemistry products will continue to be the most profitable segment of the industry and will bring in sales of $6.7 billion in 2011.
A rapidly expanding population of diabetics in need of frequent glucose monitoring will drive the predicted annual 4% jump in clinical chemistry product sales. Immunoassay products will maintain their position as the second most profitable IVD industry segment through 2011. Chemiluminiscent tests with inherent sensitivity and selectivity advantages in detecting infectious diseases will help sales of immunoassay products jump 5.3% annually to $4.9 billion in 2011, according to the report.
While clinical chemistry and immunoassays will remain the most profitable parts of the IVD industry through 2011, nucleic acid products—especially those that detect infectious disease and cancers—will generate the fastest gains, the report predicts. Sales of these products totaled $1.4 billion in 2006 and are expected to grow by 10.4% per year until 2011, when they will reach $2.3 billion. Applications used for DNA-based forensic, genetic, and identity testing will sustain the strongest gains in demand. Among other products, cellular analysis tests used in cervical cancer testing and anatomical pathology reagents and instruments used in specialized applications for cancer biopsies and detecting infectious disease will provide the best growth opportunity. The market for blood testing diagnostics will continue to post below average growth through 2011, but cardiac markers will provide niche opportunities, the report predicted.
With the healthy outlook for growth, the report also predicts major changes to the competitive structure of the IVD industry. The recent sale of Abbott’s (Abbott Park, Ill.) core diagnostic business to General Electric (Norwalk, Conn.), Siemens Medical Solutions’s (New York, N.Y.) acquisition of Bayer’s (Robinson, Pa.) diagnostic product lines, along with other major acquisition activity in the industry, will create a tough, new competitive landscape.
The report is available for purchase.